Radiation via Monoclonal Antibodies

Property	Information
Drug Name	Radiation via Monoclonal Antibodies
FDA Approval	No
Used for	Glioblastoma and potentially other high-grade glioma tumors
Clinical Trial Phase	Early to mid-stage clinical trials
Clinical Trial Explanation	Not specified
Common Side Effects	Varies; can include fatigue, headache, localized reactions at infusion site
OS without	Standard treatments for GBM typically result in a median overall survival of 14-17 months
OS with	Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts
PFS without	Median progression-free survival with standard treatments is about 6-9 months for GBM
PFS with	Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments
Usefulness Rating	3
Usefulness Explanation	Shows promise for targeted radiation delivery to tumor cells with potential for sparing normal tissue and reducing side effects, but more research is needed for a definitive assessment
Toxicity Level	3
Toxicity Explanation	Potential risks are present and may be comparable to or slightly less than traditional treatments, with concerns about toxicity under investigation

From Ben Williams Book: Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations.Property "Has original text" (as page type) with input value "Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...